Business
Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®
Study evaluated LPCN 2401 in participants with obesity (BMI ≥30) and participants with BMI ≥27 with at least one weight-related comorbidity SALT LAKE CITY,
About this update from Lipocine Inc.
[{"type":"text","content":"Study evaluated LPCN 2401 in participants with obesity (BMI ≥30) and participants with BMI ≥27 with at least one weight-related comorbidity\nSALT LAKE CITY, Sept. 5, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that a poster featuring Phase 2 data on LPCN 2401 will be presented at the Obesity Society's Annual ObesityWeek® conference to be held November 3 – 6, 2024 in San Antonio, TX.\n\n \n \n \n \n \n \n\n \nPresentation Details\nTitle\nOral LPCN 2401 Reduces Fat Mass and Increases Lean Mass in Men With Obesity\nPresenter:\nDr. Frank Greenway\nPresentation Day:\nTuesday, November 5, 2024\nPresentation Time:\n2:30 pm - 3:30 pm CT\nLocation\nExhibit Hall 4B\n \nAbout LPCN 2401\nLPCN 2401 is an oral formulation of a proprietary combination of anabolic androgen receptor agonist and α-alpha tocopherol, an antioxidant metabolic modifier. Data from preclinical and clinical studies support the potential of LPCN 2401 in gaining lean mass while losing fat mass. As adjunct therapy to incretin mimetics, LPCN 2401 has potential to attenuate weight rebound, ameliorate loss of muscle mass, improve muscle quality and functionality, amplify fat mass loss with improved body composition, and potential to maintain weight, prevent \"fat overshoot,\" and accelerate muscle rebound post incretin mimetic discontinuation.\nAbout Lipocine\nLipocine is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable benefit to risk profile which target large addressable markets with significant unmet medical needs. \nLipocine's clinical development candidates include: LPCN 1154, an oral candidate for the potential treatment of postpartum depression; LPCN 2101, an oral candidate for the potential treatment of epilepsy; LPCN 2203, an oral candidate targeted for the management of essential tremor; LPCN 2401, an oral candidate for use as an adjunct therapy to incretin mimetics or as an a...